The findings highlight the relevance of the cleaved extracellular domain of the AXL receptor, sAXL, as an early biomarker of MASLD/MASH, before the onset of histological fibrosis, and support the potential therapeutic use of AXL inhibition in preventing disease progression. This evidence concerns the gene AXL and metabolic dysfunction-associated steatotic liver disease.